

ASX Release

Change of Director's Interest Notices

PERTH, AUSTRALIA – Friday 28 June 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery ("SUDA"), releases Appendix 3Y's, Change of Director's Interest Notices, for Stephen Carter and Paul Hopper.

Stephen Carter purchased shares and options through his entitlements under the rights issue.

Paul Hopper purchased shares on-market.

The Appendix 3Y's follow.



Further information:

Stephen Carter

Managing Director/Chief Executive Officer

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety and cancer. For more information, visit www.sudapharma.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Suda Pharmaceuticals Ltd
ABN	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen John Carter
Date of last notice	3 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and shareholder of Pearlcover Investments Pty Ltd <Safeharbour Super Fund> and Pearlcover Investments Pty Ltd <SJC Family Account> as Director and beneficiary
Date of change	28 June 2019
No. of securities held prior to change	Held indirectly <ul style="list-style-type: none"> 1. 13,566,667 Ordinary Shares 2. 7,500,000 Unlisted Options (10/12/2020: 2.28 cents) 3. 6,083,333 Listed Options (SUDOC) (31/7/2020: 1.5 cents)
Class	Ordinary Shares Listed Options (30/6/2021: 1.5 cents)
Number acquired	4,522,222 Ordinary Shares 2,261,110 Listed Options (30/6/2021: 1.5 cents)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$18,089 for acquisition of 4,522,222 Ordinary Shares and 2,261,110 attaching Listed Option.
No. of securities held after change	Held indirectly <ol style="list-style-type: none"> 1. 18,088,889 Ordinary Shares 2. 7,500,000 Unlisted Options (10/12/2020: 2.28 cents) 3. 6,083,333 Listed Options (SUDOC) (31/7/2020: 1.47 cents) 4. 2,261,110 Listed Options (SUDOD) (30/6/2021: 1.5 cents)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Shares and Listed Options pursuant to the Prospectus dated 3 June 2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Dated 28 June 2019



Stephen Carter
Chief Executive Officer / Managing Director

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Suda Pharmaceuticals Ltd
ABN	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	17 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and shareholder of Moreglade Pty Ltd <The Hopper Super Fund A/c>
Date of change	27 June 2019
No. of securities held prior to change	Nil
Class	Ordinary Shares
Number acquired	1,000,000 Ordinary Shares
Number disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$4,500 for purchase of 1,000,000 Ordinary Shares
No. of securities held after change	Held indirectly 1,000,000 Ordinary Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market trade

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Dated 28 June 2019



Stephen Carter
 Chief Executive Officer / Managing Director

+ See chapter 19 for defined terms.